Mutual Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.02M | Buy |
250,040
+15,181
| +6% | +$397K | 0.11% | 175 |
|
|
2026
Q1 | $6.59M | Sell |
234,859
-8,967
| -4% | -$239K | 0.14% | 142 |
|
|
2025
Q4 | $6.07M | Buy |
243,826
+5,315
| +2% | +$134K | 0.13% | 156 |
|
|
2025
Q3 | $5.88M | Buy |
238,511
+4,970
| +2% | +$123K | 0.13% | 162 |
|
|
2025
Q2 | $5.79M | Buy |
233,541
+12,148
| +5% | +$283K | 0.14% | 154 |
|
|
2025
Q1 | $5.07M | Buy |
221,393
+20,583
| +10% | +$539K | 0.15% | 144 |
|
|
2024
Q4 | $5.32M | Sell |
200,810
-2,331
| -1% | -$63.2K | 0.15% | 128 |
|
|
2024
Q3 | $5.82M | Sell |
203,141
-7,313
| -3% | -$213K | 0.17% | 111 |
|
|
2024
Q2 | $6.47M | Sell |
210,454
-65,874
| -24% | -$1.81M | 0.2% | 102 |
|
|
2024
Q1 | $7.67M | Buy |
276,328
+59,742
| +28% | +$1.66M | 0.25% | 82 |
|
|
2023
Q4 | $6.24M | Buy |
216,586
+49,521
| +30% | +$1.5M | 0.22% | 98 |
|
|
2023
Q3 | $5.54M | Buy |
167,065
+12,692
| +8% | +$449K | 0.22% | 88 |
|
|
2023
Q2 | $5.66M | Buy |
154,373
+10,621
| +7% | +$413K | 0.21% | 95 |
|
|
2023
Q1 | $5.87M | Buy |
143,752
+8,856
| +7% | +$382K | 0.24% | 86 |
|
|
2022
Q4 | $6.91M | Buy |
134,896
+4,212
| +3% | +$202K | 0.31% | 66 |
|
|
2022
Q3 | $5.72M | Buy |
130,684
+11,643
| +10% | +$566K | 0.29% | 68 |
|
|
2022
Q2 | $6.24M | Buy |
119,041
+524
| +0.4% | +$26.7K | 0.41% | 50 |
|
|
2022
Q1 | $6.14M | Sell |
118,517
-9,189
| -7% | -$477K | 0.34% | 58 |
|
|
2021
Q4 | $7.54M | Buy |
127,706
+2,751
| +2% | +$136K | 0.4% | 47 |
|
|
2021
Q3 | $5.37M | Buy |
124,955
+6,648
| +6% | +$295K | 0.32% | 67 |
|
|
2021
Q2 | $4.63M | Sell |
118,307
-1,617
| -1% | -$62.9K | 0.27% | 85 |
|
|
2021
Q1 | $4.34M | Buy |
119,924
+8,776
| +8% | +$312K | 0.3% | 77 |
|
|
2020
Q4 | $4.09M | Buy |
111,148
+18,222
| +20% | +$668K | 0.3% | 70 |
|
|
2020
Q3 | $3.24M | Buy |
92,926
+17,411
| +23% | +$610K | 0.28% | 79 |
|
|
2020
Q2 | $2.34M | Buy |
75,515
+6,626
| +10% | +$225K | 0.23% | 103 |
|
|
2020
Q1 | $2.13M | Buy |
68,889
+8,633
| +14% | +$294K | 0.29% | 86 |
|
|
2019
Q4 | $2.24M | Buy |
60,256
+7,790
| +15% | +$277K | 0.24% | 104 |
|
|
2019
Q3 | $1.79M | Sell |
52,466
-15,437
| -23% | -$561K | 0.24% | 103 |
|
|
2019
Q2 | $2.79M | Buy |
67,903
+18,909
| +39% | +$751K | 0.36% | 57 |
|
|
2019
Q1 | $1.97M | Buy |
48,994
+819
| +2% | +$32.8K | 0.29% | 81 |
|
|
2018
Q4 | $2M | Buy |
48,175
+1,272
| +3% | +$52.8K | 0.39% | 54 |
|
|
2018
Q3 | $1.96M | Sell |
46,903
-871
| -2% | -$33.5K | 0.3% | 72 |
|
|
2018
Q2 | $1.64M | Buy |
47,774
+2,892
| +6% | +$98.8K | 0.37% | 67 |
|
|
2018
Q1 | $1.51M | Buy |
44,882
+14,734
| +49% | +$507K | 0.38% | 62 |
|
|
2017
Q4 | $1.04M | Buy |
+30,148
| New | +$1.03M | 0.39% | 80 |
|
Other funds holding PFE
Mutual Advisors's PFE Position: Q2 2026 in Review
Mutual Advisors increased its Pfizer (PFE) stake by 6.5% in Q2 2026, buying an estimated $397K and bringing the position to 250,040 shares worth $6.02M. The position accounts for 0.11% of the portfolio, ranked #175.
Mutual Advisors first reported a position in PFE in Q4 2017 and has held it in 35 quarters since. The position peaked at $7.67M in Q1 2024. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Mutual Advisors held 250,040 shares of Pfizer worth $6.02M as of Q2 2026.
- Mutual Advisors bought 15,181 Pfizer shares in Q2 2026, an estimated $397K.
- Pfizer made up 0.11% of Mutual Advisors's portfolio in Q2 2026, its #175 holding.
- Mutual Advisors first reported a position in Pfizer in Q4 2017 and has held it in 35 quarters since.
- Mutual Advisors's Pfizer position peaked at $7.67M in Q1 2024.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Mutual Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.